ClinicalTrials.gg
Not yet recruitingNCT07241156Updated Apr 9, 2026

Creative Drama on Gender Role Stress, Attitudes Toward Violence Against Women, and Aggression

An interventional study of Creative Drama Program and Film Viewing Sessions in Gender Role, Aggression and Violence, sponsored by Ataturk University. Not yet recruiting. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Ataturk University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This study aims to examine the effect of Creative Drama on gender role stress, attitudes toward violence against women, and aggression among men who experienced the February 6, 2023 earthquake in Türkiye (centered in Kahramanmaraş).

A total of 75 men (25 experimental, 25 placebo, and 25 control) will participate in the study. The experimental group will take part in a creative drama program, the placebo group will watch films focusing on masculinity roles and violence for 10 weeks, and no intervention will be applied to the control group.

Data will be collected using the Gender Role Stress Scale for Men, the Attitudes Toward Violence Against Women Scale, and the Buss-Perry Aggression Questionnaire - Short Form, and will be analyzed by an independent statistician.

The study aims to enhance the psychological well-being of men affected by the earthquake in Türkiye, reduce violence against women, and contribute to gender equality.

Read the detailed description

On February 6, 2023, two major earthquakes with magnitudes of 7.7 and 7.6 struck Türkiye, affecting 11 provinces, with Kahramanmaraş, Hatay, Adıyaman, and Malatya among the most severely impacted regions. These disasters had profound psychosocial consequences, particularly for men exposed to trauma, displacement, and post-disaster stressors that may influence gender role stress, aggression, and attitudes toward violence against women.

This study is designed as a randomized controlled experimental trial to examine the effectiveness of a Creative Drama-based psychosocial intervention among men who experienced the February 6 earthquake and currently reside in Malatya. The research will be conducted between November 2025 and December 2026.

The intervention is structured around Creative Drama, an experiential and participatory method that combines role-playing, improvisation, group interaction, and reflective discussion. The Creative Drama program will consist of 10 weekly group sessions, each designed to encourage emotional expression, critical reflection on masculinity norms, awareness of gender roles, and non-violent coping strategies. Sessions will be conducted in small groups and facilitated by a trained researcher with experience in creative drama practices.

To control for attention and group interaction effects, a placebo group will be included. Participants in this group will attend weekly sessions during which they will watch selected Turkish films addressing themes related to masculinity, gender roles, aggression, and violence against women. These sessions will not include structured discussion or therapeutic guidance. A control group will receive no intervention during the study period.

Participants will be randomly assigned to one of the three groups (experimental, placebo, or control) using a simple randomization procedure to ensure equal group sizes. Due to the nature of the intervention, blinding of participants and the researcher will not be possible. However, outcome data will be coded and analyzed by an independent statistician who will be blinded to group allocation.

Data will be collected at baseline and after completion of the intervention using standardized and validated self-report instruments. The findings of this study are expected to contribute to the development of psychosocial interventions aimed at reducing gender role stress and aggressive behaviors, promoting gender equality, and preventing violence against women in post-disaster contexts.

02

Conditions studied

  • Gender Role
  • Aggression
  • Violence

Browse trials for

Keywords

  • Creative Drama
  • Gender Role Stress
  • Attitudes Toward Violence Against Women
  • Earthquake Survivors
  • Men's Mental Health
  • Post-Disaster Psychosocial Support
  • Türkiye Earthquake 2023
  • Non-Pharmacological Intervention
03

In context

Aggression

248 studies on the registry are indexed under Aggression; 41 are open to participants now.

This study's planned enrollment of 75 is close to the median of 80 across 221 interventional studies indexed under Aggression.

Browse Aggression studies →

Lead sponsor

Ataturk University is the lead sponsor of 458 studies on the registry; 124 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male individuals who experienced the 2023 Türkiye earthquake (centered in Kahramanmaraş) and currently live in Malatya.

Married during the earthquake and currently married.

Volunteer to participate in the study.

Aged between 18 and 65 years.

No hearing or visual impairments.

No intellectual disability.

At least primary school graduate.

No diagnosed psychiatric disorder.

Have not received creative drama training.

Have not received psychosocial support after the earthquake.

Have not participated in previous studies involving creative drama related to gender role stress, attitudes toward violence against women, or aggression.

Agree to attend weekly sessions and comply with the study program.

Exclusion criteria

Exclusion Criteria:

Voluntary withdrawal from the study.

Failure to attend sessions regularly.

Changing residence to another city during the study period.

Divorce during the study period.

Beginning to receive psychosocial support during the study period.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Arm 1: Experimental Group

    Participants in this group will attend 10 weekly sessions of a Creative Drama program designed to reduce gender role stress, negative attitudes toward violence against women, and aggression.

    Behavioral: Creative Drama Program

  • Placebo comparator
    Arm 2 - Placebo Group

    Participants will watch 10 Turkish films over 10 weeks (one per week) containing themes of masculinity, violence against women, and aggression.

    Behavioral: Film Viewing Sessions

  • No intervention
    Arm 3 - Control Group

    Participants in this group will not receive any intervention during the study period.

Interventions

  • BehavioralCreative Drama Program

    A structured 10-week Creative Drama program designed to reduce gender role stress, negative attitudes toward violence against women, and aggressive behaviors. Each session will include warm-up activities, improvisation, role-playing, and reflection components. Sessions will be conducted once a week for 90 minutes by a certified drama educator.

  • BehavioralFilm Viewing Sessions

    Participants in the placebo group will watch 10 Turkish films over a 10-week period (one per week) that include themes of masculinity, gender roles, and violence. This intervention is designed as an attention-control condition to match the structure of the experimental group without providing therapeutic content.

06

What researchers measure

Primary outcomes

  1. Change in Male Gender Role Stress Levels

    To evaluate the effect of the Creative Drama Program on gender role stress among men who experienced the 2023 Türkiye earthquake. The Gender Role Stress Scale for Men will be used to measure changes in perceived gender-related stress. The minimum score that can be obtained from the scale is 27, and the maximum score is 130. Higher scores indicate a higher level of gender role stress in the individual.

    Time frame: Baseline (Week 0) and 10 weeks after intervention

  2. Change in Attitudes Toward Violence Against Women

    To assess the impact of the Creative Drama Program on men's attitudes toward violence against women. The Attitudes Toward Violence Against Women Scale will be administered to measure changes in participants' beliefs and attitudes. For the overall scale, the minimum possible score is 30 and the maximum score is 150. Higher scores indicate a negative attitude toward violence against women (i.e., the individual is opposed to violence against women), whereas lower scores indicate a positive attitude toward violence against women (i.e., the individual is not opposed to violence against women).

    Time frame: Baseline (Week 0) and 10 weeks after intervention

  3. Change in Aggression Levels

    To determine the effect of the Creative Drama Program on aggression among male earthquake survivors. The Buss-Perry Aggression Questionnaire - Short Form will be used to assess total aggression and subscale scores (physical aggression, verbal aggression, anger, and hostility). For the overall scale, the minimum possible score is 29 and the maximum score is 145. As the score increases, the level of aggression also increases.

    Time frame: Baseline (Week 0) and 10 weeks after intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — The individual participant data (IPD) will not be shared due to ethical considerations and the sensitivity of personal information collected from earthquake survivors. Only aggregated results will be published in scientific journals.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Apr 2026, 1 month later.

Of 93 non-industry interventional studies with no phase under Aggression, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 1 month is below that.

Counting every sponsor, half of 93 studies reached it within 22 months; a quarter within 13 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartEst.
Mar 30, 2026
Primary completionEst.
Apr 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07241156
Lead sponsor
Ataturk University
Responsible party
Aslı SİS ÇELİK (Professor, Ataturk University) — Principal investigator
First posted
Nov 21, 2025
Start date
Mar 30, 2026 (estimated)
Primary completion
Apr 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Apr 9, 2026

Study contacts

Aslı SİS ÇELİK
Contact
aslisis@atauni.edu.tr
+905434668242
Sevim LEVENT
Contact
aslisis@atauni.edu.tR
+905066040730
Aslı SİS ÇELİK
study director · Ataturk University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion